AstraZeneca is paying up to Shanghai-based LaNova Medicines for one of the biotech’s preclinical stage antibody-drug conjugates (ADC), dubbed LM-305, following a licensing deal earlier this year for another China-developed ADC.
LaNova Medicines Ltd. announced it has entered into an exclusive license agreement with AstraZeneca, for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).